Status: Finalised
First registered on:
26/10/2017
Last updated on:
03/05/2021
1. Study identification
EU PAS Register NumberEUPAS21359
Official titleAnti-microbial resistance: choice of therapeutic interventions and outcomes for the treatment of infections caused by MDR Gram-negative pathogens
Study title acronym
Study typeObservational study
Brief description of the studyA systematic literature review of all available treatment guidelines and recommendations and the evidence behind them, and a European cross-sectional six-country survey of antibiotic prescribing patterns and algorithms used in clinical practice. As added values, we will include an MDR treatment outcome analysis using existing Danish data and, if accessible, other European individual-level hospital data.
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Department/Research groupDepartment of Clinical Epidemiology
Organisation/affiliationAarhus University / Aarhus University Hospital
Details of (Primary) lead investigator
Title Professor
Last name Sørensen
First name Henrik Toft
Is this study being carried out with the collaboration of a research network?
Yes
Aarhus University Consortium (ad hoc)
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
International study
Denmark
France
Greece
Netherlands
Romania
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed17/03/201717/03/2017
Start date of data collection17/06/201717/06/2017
Start date of data analysis
Date of interim report, if expected
Date of final study report17/11/201812/10/2018
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companies
Charities
Government body
Research councils
EU funding schemeEuropean Medicines Agency100
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Ehrenstein
First name Vera
Address line 1Department of Clinical Epidemiology
Address line 2Aarhus University Hospital
Address line 3
CityAarhus
Postcode
CountryDenmark
Phone number (incl. country code)45-87168063
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Professor
Last name Sørensen
First name Henrik Toft
Address line 1Olof Palmes Allé 43-45
Address line 2
Address line 3
CityAarhus N
Postcode8200
CountryDenmark
Phone number (incl. country code)45-87168063
Alternative phone number
Fax number (incl. country code)45-87167215
6. Study drug(s) information
Substance class (ATC Code)J01 (AMPHENICOLS)
7. Medical conditions to be studied
Medical condition(s)No
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects1200000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources registered with ENCePP
Sources of data
Administrative database, e.g. claims database
Pharmacy dispensing records
Surveys
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Primary scope : Disease epidemiology
12. Main objective(s)
What is the main objective of the study?
Systematic review of all available treatment guidelines and recommendations and the evidence behind them, and a European cross-sectional six-country survey of antibiotic prescribing patterns and algorithms used in clinical practice. As added value, we will include an MDR treatment outcome analysis using existing Danish data and, if accessible, other European individual-level data.
Are there primary outcomes?No
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
cross-sectional survey
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
min 12 months
15. Data analysis plan
Please provide a brief summary of the analysis method
Systematic review of all available treatment guidelines and recommendations and the evidence behind them, and a European cross-sectional six-country survey of antibiotic prescribing patterns and algorithms used in clinical practice. As added value, we will include an MDR treatment outcome analysis using existing Danish data and, if accessible, other European individual-level data.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
Nørgaard SM, Jensen CS, Aalestrup J, et al. Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review. Antimicrob Resist Infect Control 2019;8:170. doi: 10.1186/s13756-019-0624-1 [published Online First: 2019/11/12]https://pubmed.ncbi.nlm.nih.gov/31709047/
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
